Gastroenterology
Volume 135, Issue 4 , Pages 1130-1141 , October 2008

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Data were presented on May 21, 2007 at Digestive Disease Week 2007 (Washington, DC).

  • William J. Sandborn

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationCorresponding author: William J. Sandborn, MD, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. fax: (507) 266-0335
    • ,
  • Brian G. Feagan

      Affiliations

    • London Health Sciences Center, London, Ontario, Canada
    • ,
  • Richard N. Fedorak

      Affiliations

    • Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Ellen Scherl

      Affiliations

    • Jill Roberts Inflammatory Bowel Disease Center, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York
    • ,
  • Mark R. Fleisher

      Affiliations

    • Borland–Groover Clinic, Jacksonville, Florida
    • ,
  • Seymour Katz

      Affiliations

    • Long Island Clinical Research Associates, LLP, Great Neck, New York
    • ,
  • Jewel Johanns

      Affiliations

    • Clinical Biostatistics, Centocor, Inc, Malvern, Pennsylvania
    • ,
  • Marion Blank

      Affiliations

    • Clinical Biostatistics, Centocor, Inc, Malvern, Pennsylvania
    • ,
  • Paul Rutgeerts

      Affiliations

    • University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Ustekinumab Crohn's Disease Study Group

Received 15 April 2008 ,Accepted 10 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Some of the results presented in this article were previously published in abstract form in Gastroenterology 2007;132(Suppl 2):A-51.

 Centocor, Inc (Malvern, PA) provided support for this study (C0379T07; clinical trials registration: clinicaltrials.gov #NCT00265122). Marion Blank and Jewel Johanns are employees of Centocor, Inc; William J. Sandborn received research funding in conjunction with the conduct of this study, he also received a research grant (1-UL1-RR024150-01) from the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research and is a consultant to Centocor, Inc (fees paid to the Mayo Clinic); Brian G. Feagan received research funding in conjunction with the conduct of this study, he also received other research grants and is a consultant to Centocor, Inc; Richard N. Fedorak received research funding in conjunction with the conduct of this study; Ellen Scherl received research funding in conjunction with the conduct of this study and other research grants and served as a consultant to Centocor, Inc; Mark R. Fleischer received research funding in conjunction with the conduct of this study and speaker payments, and has served as a consultant to Centocor, Inc; Seymour Katz received research funding in conjunction with the conduct of this study and other research grants from Centocor, Inc; Paul Rutgeerts received research funding in conjunction with the conduct of this study, he also received other research grants and speaker payments, and is a consultant to Centocor, Inc.

 Members of the Ustekinumab Crohn's Disease Study Group are listed at the end of the article.

PII: S0016-5085(08)01322-X

doi: 10.1053/j.gastro.2008.07.014

Gastroenterology
Volume 135, Issue 4 , Pages 1130-1141 , October 2008

Article Tools

* Image Usage & Resolution